Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(28)
•••
Comment by pabalooon Feb 21, 2020 10:00pm
67 Views
Post# 30720291

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:5 to 7 dollars a share!!!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:5 to 7 dollars a share!!!!Who's with you? No one! Are you out of your mind swapper? Sell your 50 shares and move on man. The Mulls alone will need to direct this ship to paradise. Try ousting them and paying them off and the company would be broke moron. Everyone on this board has clauses in there contract if there removed! If your not on management side sell and move on. The number one reason you own a stock is good management, I know it's questionable here but there is No alternative unless the Mulls appoint someone. Also Selling absorica to Sun is just my fantasy, it's not a rumour I herd at the coffee shop. Just makes sense they would buy it out and market all of it and the generic in a few years and pay a premium for the rights. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities